BRAF and melanoma: Because over 50% of melanoma patients harbor oncogenic mutations in BRAF and BRAF-mutant melanoma cells depend upon BRAF mutations for the growth and survival, several BRAF inhibitors (BRAFi) have been approved by the US Food and Drug Administration (US FDA), including vemurafenib and dabrafenib, for the clinical treatment of metastatic melanoma15,16.